FindTrial
Sign In

Identification of biomarkers and pathogenesis of lung cancer without targeted metabolomics based on uplc-q-tof /MS

Identification of biomarkers and pathogenesis of lung cancer without targeted metabolomics based on uplc-q-tof /MS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025543
Enrollment
Unknown
Registered
2019-08-31
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:No Intervention

Sponsors

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. in line with the standard of diagnosis and treatment of common malignant tumors compiled by the medical department of the People's Republic of China,Patients with lung malignancy diagnosed by pathology or cytology; 2. the survival period was estimated to be more than 3 months. In general, Karnorfsy=30 points, ecog-ps for 2 months; 5. patients are willing to accept the program, compliance.

Exclusion criteria

Exclusion criteria: 1. does not meet the inclusion criteria; 2. pregnant or lactating women; 3. combined with serious cardiovascular and cerebrovascular diseases, or mental disorders and other diseases; 4. participate in other clinical trials; 5. Poor compliance.

Design outcomes

Primary

MeasureTime frame
potential differential metabolites of lung cancer;—

Countries

China

Contacts

Public ContactChenchen Zhao

New campus of Tianjin University of Traditional Chinese Medicine, Tianjin, China

1032903124@qq.com+86 15902252036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026